No material company-specific news briefings were available in the verified context for the period ending 2026-09-11. The most recent regulatory filings and institutional ownership disclosures as of the generation date informed this report [Brief - 2026-08-15]. Medtronic plc continued to operate across its established medical device segments during this period, with no material corporate announcements identified in the verified briefing sources for the 30 days preceding the generation date of 2026-09-27 [Brief - 2026-09-19].
As of the quarter ending 2026-07-31, Medtronic recorded trailing twelve-month revenue of $37.54 billion, representing year-over-year growth of 13.73%. Net income on a TTM basis stood at approximately $430 million, producing a net margin of 1.15%. Gross margin was 51.95% and operating margin was 18.08%. EPS grew 40.74% year-over-year on a TTM basis. The company held $1.69 billion in cash against total debt of $24.68 billion. Market capitalisation was approximately $113.46 billion, with a P/E ratio of 21.83 [SEC 10-Q - MDT - 2026-07-31].
Insider activity in September 2026 recorded two transactions, both in the selling direction, with a combined net value of approximately -$138,883 [SEC Form 4 - MDT - 2026-09]. On the institutional side, four notable firms initiated new positions in MDT during the most recent reporting period: Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio) each opened new positions, representing the material institutional position changes that triggered this report [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macro environment as of the generation date shows the 10-year US Treasury yield at 5.18% and the 2-year at 4.87%, with the yield curve in a normal configuration [FRED DGS10] [FRED DGS2]. The elevated rate environment is a relevant backdrop for a company carrying $24.68 billion in total debt, as financing costs remain a material consideration in interpreting balance sheet data [SEC 10-Q - MDT - 2026-07-31].